Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364907 | 0.83 | MRGPRX4 (0.53) | TDP1SCN9AMRGPRX4 | |
| SCHEMBL662496 | 0.80 | NPC1 (0.46) | MRGPRX4ALDH1A1MAPK1PTGER1 | |
| SCHEMBL15543295 | 0.78 | SCN9A (0.61) | SCN9A | |
| SCHEMBL15094290 | 0.74 | SCN9A (0.44) | SCN9A | |
| SCHEMBL10198138 | 0.73 | SCN9A (0.44) | SCN9A | |
| SCHEMBL16174920 | 0.72 | SCN9A (0.49) | SCN9A | |
| SCHEMBL13304082 | 0.72 | MTNR1A (0.47) | SCN9AMAPK1AAK1 | |
| SCHEMBL1690323 | 0.71 | SCN9A (0.49) | SCN9A | |
| SCHEMBL12302707 | 0.71 | MTNR1A (0.37) | TDP1ALDH1A1MAPK1 | |
| SCHEMBL16175358 | 0.70 | SCN9A (0.54) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2791108-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088315-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | P2RX3 147/4885TDP1 2070/4885SCN9A 20/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | P2RX3 3760/4885TDP1 3922/4885SCN9A 4625/4885 |
| US-20140315879-A1 | Sulfonamide Derivatives | SCN7A, SCN1B, SCN1A | P2RX3 105/4885TDP1 3327/4885SCN9A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.